Recent executive actions have shaped trader views on marijuana rescheduling timelines. President Trump’s December 2025 executive order directed expedited movement of cannabis from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately reclassifying FDA-approved products and state-licensed medical marijuana to Schedule III, while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing began June 29, 2026, and was set to conclude by July 15. The process now centers on the administrative law judge’s recommendations and any subsequent rulemaking, with no final decision yet issued for non-medical cannabis. These verified steps, rather than earlier stalled proceedings, underpin current market pricing on resolution dates.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日$796,389 Vol.
2026/03/31
9月30日
14%
12月31日
23%
$796,389 Vol.
9月30日
$0 Vol.
14%
12月31日
$186,818 Vol.
23%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have shaped trader views on marijuana rescheduling timelines. President Trump’s December 2025 executive order directed expedited movement of cannabis from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately reclassifying FDA-approved products and state-licensed medical marijuana to Schedule III, while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing began June 29, 2026, and was set to conclude by July 15. The process now centers on the administrative law judge’s recommendations and any subsequent rulemaking, with no final decision yet issued for non-medical cannabis. These verified steps, rather than earlier stalled proceedings, underpin current market pricing on resolution dates.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
マーケット開始日： Feb 7, 2026, 5:04 PM ET
音量
$796,389終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have shaped trader views on marijuana rescheduling timelines. President Trump’s December 2025 executive order directed expedited movement of cannabis from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately reclassifying FDA-approved products and state-licensed medical marijuana to Schedule III, while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing began June 29, 2026, and was set to conclude by July 15. The process now centers on the administrative law judge’s recommendations and any subsequent rulemaking, with no final decision yet issued for non-medical cannabis. These verified steps, rather than earlier stalled proceedings, underpin current market pricing on resolution dates.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
音量
$796,389終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive actions have shaped trader views on marijuana rescheduling timelines. President Trump’s December 2025 executive order directed expedited movement of cannabis from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately reclassifying FDA-approved products and state-licensed medical marijuana to Schedule III, while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing began June 29, 2026, and was set to conclude by July 15. The process now centers on the administrative law judge’s recommendations and any subsequent rulemaking, with no final decision yet issued for non-medical cannabis. These verified steps, rather than earlier stalled proceedings, underpin current market pricing on resolution dates.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問